This application is for renewal of a grant that we have had since 2001. Its purpose is to understand how interactions of CREB and kappa-opioid receptor (KOR) systems in the nucleus accumbens shell (NAs) affect behavior in the context of mood and anxiety disorders. Our 9 years of support has led to discoveries that have had a significant impact on the field: (i) stress activates CREB in the NAs;(ii) elevated CREB function in the NAs triggers depressive-like behaviors;(iii) depressive-like behaviors are induced by CREB-mediated increases in dynorphin actions at KORs;(iv) KOR antagonists have antidepressant-like effects;and (v) KOR antagonists have anxiolytic-like effects. Our work has provided new insights on the role of the NAs in encoding rewarding and aversive states, and led directly to drug development efforts in academia and industry. Our over-arching hypothesis is that stress-induced CREB activation in the NAs increases dynorphin expression, which enhances feedback inhibition of the mesocorticolimbic system. This process triggers behaviors characteristic of depressive and, as new evidence suggests, anxiety-related disorders. Our continuing studies are designed to determine how modifications to this CREB-KOR cascade can cause and protect against the persistent effects of stress, using models that quantify key signs of depression and co-morbid disorders.
In Aim 1, we will test the hypothesis that elevated CREB function in the NAs produces behavioral signs common to depressive and frequently co-morbid anxiety disorders such as post-traumatic stress disorder (PTSD). We will use an attention test to examine if elevated CREB in the NAs produces deficits in concentration and decision-making that are hallmark signs of major depression and PTSD. We will also use an inhibition-of-fear test to examine if elevated CREB in the NAs produces deficits in sensitivity to safety signals that characterize PTSD but not depression.
In Aim 2, we will test the hypothesis that disruption of KOR function in the mesocorticolimbic system prevents the development of depressive and anxiety-related behaviors. We have made a line of mice in which the KOR gene is floxed, and found that ablation of KORs in all brain areas expressing dopamine uptake transporter (DAT) attenuates stress-related behavioral adaptations. We will use viral vectors to determine if further restriction of KOR ablation to the mesocorticolimbic system during adulthood produces similar resistance to stress. We will use tests (fear conditioning;intracranial self- stimulation) that quantify hallmark signs of depression and anxiety while providing insight on any non-specific effects of our manipulations.
In Aim 3, we will test the hypothesis that disruption of KOR function prevents stress effects via actions that involve reduced sensitivity to corticotropin releasing factor (CRF), and that the long-lasting anti-stress effects of KOR antagonists require activation of c-Jun N-terminal kinase (JNK). We will also test the hypothesis that KOR disruption blocks stress-induced alterations in microRNA (miR) expression in the mesocorticolimbic system. This work may provide a basis for improved diagnostics and therapeutics.

Public Health Relevance

This research examines the mechanisms by which stress-induced alterations in the function of the transcription factor CREB and kappa-opioid receptor (KOR) systems trigger depressive and anxiety-related behavior. Our proposed studies are designed to determine how modifications to this CREB-KOR cascade can cause and protect against the persistent effects of stress, using animal models that quantify hallmark signs of depression and anxiety disorders in humans. This work may provide a basis for improved diagnosis, treatment, and prevention of mental illness.

Agency
National Institute of Health (NIH)
Type
Research Project (R01)
Project #
5R01MH063266-14
Application #
8651943
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Meinecke, Douglas L
Project Start
Project End
Budget Start
Budget End
Support Year
14
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Mclean Hospital
Department
Type
DUNS #
City
Belmont
State
MA
Country
United States
Zip Code
02478
Muschamp, John W; Hollander, Jonathan A; Thompson, Jennifer L et al. (2014) Hypocretin (orexin) facilitates reward by attenuating the antireward effects of its cotransmitter dynorphin in ventral tegmental area. Proc Natl Acad Sci U S A 111:E1648-55
Donahue, Rachel J; Muschamp, John W; Russo, Scott J et al. (2014) Effects of striatal ?FosB overexpression and ketamine on social defeat stress-induced anhedonia in mice. Biol Psychiatry 76:550-8
Chartoff, Elena H; Carlezon Jr, William A (2014) Drug withdrawal conceptualized as a stressor. Behav Pharmacol 25:473-92
Rauch, Scott L; Carlezon Jr, William A (2013) Neuroscience. Illuminating the neural circuitry of compulsive behaviors. Science 340:1174-5
Muschamp, John W; Carlezon Jr, William A (2013) Roles of nucleus accumbens CREB and dynorphin in dysregulation of motivation. Cold Spring Harb Perspect Med 3:a012005
Van't Veer, Ashlee; Bechtholt, Anita J; Onvani, Sara et al. (2013) Ablation of kappa-opioid receptors from brain dopamine neurons has anxiolytic-like effects and enhances cocaine-induced plasticity. Neuropsychopharmacology 38:1585-97
Coleman, Brian R; Carlezon Jr, William A; Myers, Karyn M (2013) Extinction of conditioned opiate withdrawal in rats is blocked by intracerebroventricular infusion of an NMDA receptor antagonist. Neurosci Lett 541:39-42
Van't Veer, Ashlee; Carlezon Jr, William A (2013) Role of kappa-opioid receptors in stress and anxiety-related behavior. Psychopharmacology (Berl) 229:435-52
McDougle, Christopher J; Carlezon Jr, William A (2013) Neuroinflammation and autism: toward mechanisms and treatments. Neuropsychopharmacology 38:241-2
Muschamp, John W; Nemeth, Christina L; Robison, Alfred J et al. (2012) ýýFosB enhances the rewarding effects of cocaine while reducing the pro-depressive effects of the kappa-opioid receptor agonist U50488. Biol Psychiatry 71:44-50

Showing the most recent 10 out of 55 publications